Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oncotelic Therapeutics, Inc. (OTLC)
USD0.04
+0.00 (+0.29%)
US OTC Healthcare Biotechnology
Address
29397 Agoura Road 91301
Agoura Hills, CA, US
Agoura Hills, CA, US
CEO
Vuong Trieu
Website
oncotelic.com
IPO
1993-08-26
CIK 908259 ISIN US6283411097
Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
News Sentiment (7d)
Based on only 2 articles — low confidence
- Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway GlobeNewsWire
- Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway Globe News Wire
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| OXiGENE | OXGN | 2009-11-30 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.04
+0.00 (+0.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
279.6K
Beta
-0.27
Float Shares
223.86M
Free Float %
50.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.35% | +44.77% | +42.11% | +17.39% | -43.10% | -31.12% | -5.43% | +50.00% | -82.00% | -90.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.04
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.05
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+5,367.9% ★ Q1'26: -600.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%+0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.1% Q1'26: +8.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×— Q1'26: -2,265,112.62× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2020 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|
| Revenue |
—
est: 100.0K (-100.0%)
|
1.74M
est: 1.72M (+1.2%)
|
70.0K
est: 70.0K (+0.0%)
|
—
|
| EBITDA |
-13.63M
est: 20.0K (-68,273.4%)
|
-7.61M
est: 344.1K (-2,311.4%)
|
-7.16M
est: 14.0K (-51,255.6%)
|
-3.55M
|
| EBIT |
-13.65M
est: 20.0K (-68,373.4%)
|
-7.97M
est: 344.1K (-2,417.2%)
|
-7.16M
est: 14.0K (-51,255.6%)
|
-3.92M
|
| Net Income |
-13.65M
est: -214.33M (+93.6%)
|
-11.50M
est: -32.35M (+64.5%)
|
-7.90M
est: -8.09M (+2.3%)
|
-4.52B
|
| SGA |
4.60M
est: 281.6K (+1,531.9%)
|
5.02M
est: 4.85M (+3.7%)
|
573.7K
est: 197.1K (+191.0%)
|
376.0K
|
| EPS |
-0.54
est: -0.53 (-1.9%)
|
-0.13
est: -0.08 (-62.5%)
|
-0.02
est: -0.02 (+0.0%)
|
-0.01
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 3/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 3/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-342.24B
OE per share TTM
-771.16
Owner's Yield
-1,428,085.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abrams Capital Management, L.P. | 25.00M | 4.74% | — | 1.98M | — | 1.98M | PN | Cayman Islands | 2017-01-05 | ↗ |
| 2 | First Trust Portfolios L.P., First Trust Advisors L.P., The Charger Corporation | 9.66M | 8.25% | — | 2.07M | — | 2.07M | BD, IA, HC | Delaware, USA | 2015-01-08 | ↗ |
| 3 | AM Investment Partners, LLC | 3.78M | 5.16% | — | 3.78M | — | — | OO | Delaware, U.S.A. | 2010-05-19 | ↗ |
| 4 | Adam Stern | 3.78M | 5.16% | — | 3.78M | — | — | IN | United States of America | 2010-05-19 | ↗ |
| 5 | Mark Friedman | 3.78M | 5.16% | — | 3.78M | — | — | IN | United States of America | 2010-05-19 | ↗ |
| 6 | BARCLAYS GLOBAL INVESTORS, NA. | 2.38M | 5.32% | — | 205.3K | — | 205.3K | BK | USA | 2013-04-18 | ↗ |
| 7 | 10. | 1.85M | 6.90% | — | — | — | 1.85M | HC, IN | United States of America | 2015-03-31 | ↗ |
| 8 | BAM Management, LLC | 1.80M | 1.64% | — | 1.80M | — | 1.80M | OO | United States of America | 2011-01-10 | ↗ |
| 9 | BAM Opportunity Fund SPV, LLC | 1.80M | 1.64% | — | 1.80M | — | 1.80M | OO | United States of America | 2011-01-10 | ↗ |
| 10 | Hal Mintz | 1.80M | 1.64% | — | 1.80M | — | 1.80M | IN | United States of America | 2011-01-10 | ↗ |
| 11 | Ross Berman | 1.80M | 1.64% | — | 1.80M | — | 1.80M | IN | United States of America | 2011-01-10 | ↗ |
| 12 | 13G/A | 1.31M | 4.70% | — | 1.31M | — | 1.31M | IA, PN | Texas | 2016-02-05 | ↗ |
| 13 | Page 2 of 4 Pages | 1.02M | 8.92% | 1.02M | — | 1.02M | — | EP, IN | Liechtenstein | 2014-02-21 | ↗ |
| 14 | 13G | 10.00 | 12.00% | — | 2.27M | — | 2.27M | CO | Texas | 2015-03-30 | ↗ |
| 15 | BAM Capital, LLC | — | 0.00% | — | — | — | — | OO | Delaware USA | 2010-01-12 | ↗ |
| 16 | BAM Opportunity Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware USA | 2010-01-12 | ↗ |
| 17 | Capital Ventures International | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2016-02-12 | ↗ |
| 18 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2016-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
4.1K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+4,065
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 4,426 | 0.00 | — | 8,491 | D | ↗ |
| 2025-11-17 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 4,065 | 0.00 | — | 4,065 | D | ↗ |
| 2025-07-10 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 104,000 | 0.01 | 520.00 | 93,293,560 | D | ↗ |
| 2025-07-09 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1 | 0.01 | 0.01 | 93,293,561 | D | ↗ |
| 2025-07-08 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 94,736 | 0.01 | 473.68 | 93,388,297 | D | ↗ |
| 2025-01-31 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 63,775 | 0.03 | 1.8K | 93,189,560 | D | ↗ |
| 2025-01-30 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,003 | 0.03 | 2.8K | 93,125,785 | D | ↗ |
| 2025-01-29 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 183,066 | 0.03 | 5.1K | 93,025,782 | D | ↗ |
| 2024-11-22 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 298,499 | 0.03 | 8.6K | 92,842,716 | D | ↗ |
| 2024-08-23 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500,000 | 0.02 | 10.0K | 92,544,217 | — | ↗ |
| 2023-06-29 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 425,000 | 0.02 | 8.9K | 92,044,217 | — | ↗ |
| 2023-06-28 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 75,000 | 0.03 | 2.0K | 91,619,217 | — | ↗ |
| 2023-06-16 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.03 | 2.6K | 91,544,217 | — | ↗ |
| 2023-06-14 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 400,000 | 0.03 | 13.0K | 91,444,217 | — | ↗ |
| 2023-05-26 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 126,888 | 0.03 | 4.3K | 91,044,217 | — | ↗ |
| 2023-05-02 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.05 | 4.5K | 90,917,329 | — | ↗ |
| 2022-12-06 | Trieu Vuong | Officer | P-Purchase | A | Common Stock | 120,000 | 0.05 | 6.0K | 90,558,021 | — | ↗ |
| 2022-11-22 | Trieu Vuong | Officer | P-Purchase | A | Common Stock | 70,000 | 0.08 | 5.6K | 90,438,021 | — | ↗ |
| 2022-09-26 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.07 | 1.4K | 90,368,021 | — | ↗ |
| 2022-08-25 | Trieu Vuong | Officer | P-Purchase | A | Common Stock | 80,000 | 0.08 | 6.6K | 90,348,021 | — | ↗ |
| 2021-09-03 | Trieu Vuong | Officer | A-Award | A | Stock Options | 225,000 | 0.00 | — | 225,000 | — | ↗ |
| 2021-09-03 | Saund Saran | Officer | A-Award | A | Stock Options | 675,000 | 0.14 | 94.0K | 675,000 | — | ↗ |
| 2021-09-03 | MAIDA ANTHONY E III | Director / Officer | A-Award | A | Stock Options | 600,000 | 0.14 | 83.6K | 600,000 | — | ↗ |
| 2021-09-03 | KING STEVEN W | Director | A-Award | A | Stock Options | 500,000 | 0.14 | 69.7K | 500,000 | — | ↗ |
| 2021-07-08 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Stock Options | 513,953 | 0.16 | 83.6K | 513,953 | — | ↗ |
| 2021-07-08 | Shah Amit B. | Officer | A-Award | A | Stock Options | 698,256 | 0.16 | 113.5K | 698,256 | — | ↗ |
| 2021-07-08 | Saund Saran | Officer | A-Award | A | Stock Options | 216,279 | 0.16 | 35.2K | 216,279 | — | ↗ |
| 2021-07-08 | MAIDA ANTHONY E III | Director / Officer | A-Award | A | Stock Options | 400,000 | 0.16 | 65.0K | 400,000 | — | ↗ |
| 2021-07-08 | KING STEVEN W | Director | A-Award | A | Stock Options | 357,412 | 0.16 | 58.1K | 357,412 | — | ↗ |
| 2021-07-08 | Diamond David | Director | A-Award | A | Stock Options | 451,467 | 0.16 | 73.4K | 451,467 | — | ↗ |
| 2021-03-31 | Trieu Vuong | Director / Officer / 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 5,672 | 0.00 | — | 0 | — | ↗ |
| 2021-03-31 | Saund Saran | Officer | C-Conversion | A | Common Stock | 16,354,961 | 0.00 | — | 16,354,961 | — | ↗ |
| 2021-03-31 | MAIDA ANTHONY E III | Director / Officer | C-Conversion | A | Common Stock | 938,646 | 0.00 | — | 1,137,314 | — | ↗ |
| 2021-03-31 | KING STEVEN W | Director | C-Conversion | D | Series A Convertible Preferred Stock | 3,292 | 0.00 | — | 0 | — | ↗ |
| 2020-11-24 | Shah Amit B. | Officer | P-Purchase | A | Common Stock | 8,220 | 0.19 | 1.6K | 60,000 | — | ↗ |
| 2020-11-23 | Shah Amit B. | Officer | P-Purchase | A | Common Stock | 20,088 | 0.19 | 3.8K | 51,780 | — | ↗ |
| 2020-11-20 | Shah Amit B. | Officer | P-Purchase | A | Common Stock | 31,692 | 0.20 | 6.2K | 31,692 | — | ↗ |
| 2020-11-19 | Trieu Vuong | Officer | P-Purchase | A | Common Stock | 50,500 | 0.19 | 9.6K | 15,812,308 | — | ↗ |
| 2020-11-19 | Park Chulho | Officer | P-Purchase | A | Common Stock | 22,173 | 0.18 | 4.1K | 2,833,992 | — | ↗ |
| 2020-05-11 | MAIDA ANTHONY E III | Director | — | D | Series A Convertible Preferred Stock | 938,646 | 0.00 | — | 0 | — | ↗ |
| 2020-05-11 | KING STEVEN W | Director | — | D | Common Stock | 0 | 0.00 | — | 696,704 | — | ↗ |
| 2020-03-26 | Trieu Vuong | Officer | P-Purchase | A | Common Stock | 3,000 | 0.12 | 360.00 | 15,761,808 | — | ↗ |
| 2020-01-22 | Diamond David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-22 | Uckun Fatih | Officer / 10% Owner | — | D | Series A Convertible Preferred Stock | 7,052,762 | 0.00 | — | 0 | — | ↗ |
| 2019-04-22 | Trieu Vuong | Director / Officer / 10% Owner | — | I | Series A Convertible Preferred Stock | 5,672,025 | 0.00 | — | 0 | — | ↗ |
| 2019-04-22 | Park Chulho | Officer / 10% Owner | — | D | Series A Convertible Preferred Stock | 13,285,013 | 0.00 | — | 0 | — | ↗ |
| 2019-04-22 | Hwang Larn | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,095,581 | — | ↗ |
| 2019-04-22 | Hsiao Chao | 10% Owner | — | D | Series A Convertible Preferred Stock | 14,070,529 | 0.00 | — | 0 | — | ↗ |
| 2018-06-20 | Schwieterman William D | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2018-06-20 | SANDAGE BOBBY W. JR., PHD. | Director | A-Award | A | Stock Option (Right to Buy) | 258,171 | 0.22 | 56.8K | 258,171 | — | ↗ |
| 2018-06-20 | Reynolds Donald Rogers | Director | A-Award | A | Stock Option (Right to Buy) | 258,171 | 0.22 | 56.8K | 258,171 | — | ↗ |
| 2018-06-20 | Pedder Simon | Director | A-Award | A | Stock Option (Right to Buy) | 258,171 | 0.22 | 56.8K | 258,171 | — | ↗ |
| 2018-06-20 | LOAR MATTHEW M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2018-06-20 | CHAPLIN DAVID | Director | A-Award | A | Stock Option (Right to Buy) | 258,171 | 0.22 | 56.8K | 258,171 | — | ↗ |
| 2018-04-12 | Schwieterman William D | Director / Officer | P-Purchase | A | Common Stock A Warrant (Right to Buy) | 312,500 | 0.40 | 125.0K | 312,500 | — | ↗ |
| 2018-04-12 | Reynolds Donald Rogers | Director | P-Purchase | A | Common Stock A Warrants (Right to Buy) | 125,000 | 0.40 | 50.0K | 125,000 | — | ↗ |
| 2018-04-12 | LOAR MATTHEW M | Officer | P-Purchase | A | Common Stock B Warrant (Right to Buy) | 125,000 | 0.40 | 50.0K | 125,000 | — | ↗ |
| 2017-06-09 | SANDAGE BOBBY W. JR., PHD. | Director | A-Award | A | Stock Option (Right to Buy) | 121,483 | 0.51 | 62.0K | 121,483 | — | ↗ |
| 2017-06-09 | Reynolds Donald Rogers | Director | A-Award | A | Stock Option (Right to Buy) | 121,483 | 0.51 | 62.0K | 121,483 | — | ↗ |
| 2017-06-09 | Pedder Simon | Director | A-Award | A | Stock Option (Right to Buy) | 121,483 | 0.51 | 62.0K | 121,483 | — | ↗ |
| 2017-01-12 | Schwieterman William D | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 550,000 | 0.38 | 206.3K | 550,000 | — | ↗ |
| 2017-01-12 | CHAPLIN DAVID | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 262,500 | 0.38 | 98.4K | 262,500 | — | ↗ |
| 2016-12-16 | Reynolds Donald Rogers | Director | P-Purchase | A | Common Stock, $.01 par value per share | 9,950 | 0.36 | 3.5K | 30,000 | — | ↗ |
| 2016-10-25 | SANDAGE BOBBY W PHD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-10-25 | Reynolds Donald Rogers | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-06-01 | Pedder Simon | Director | A-Award | A | Stock Option (Right to Buy) | 91,564 | 0.00 | — | 91,564 | — | ↗ |
| 2016-06-01 | McMahon Gerald PhD | Director | A-Award | A | Stock Option (Right to Purchase) | 91,564 | 0.65 | 59.5K | 91,564 | — | ↗ |
| 2016-06-01 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 91,564 | 0.65 | 59.5K | 91,564 | — | ↗ |
| 2016-03-21 | Schwieterman William D | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 500,000 | 0.73 | 363.9K | 500,000 | — | ↗ |
| 2016-03-21 | Pedder Simon | Director | A-Award | A | Stock Option (Right to Buy) | 99,711 | 0.73 | 72.6K | 99,711 | — | ↗ |
| 2016-03-21 | LOAR MATTHEW M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 262,500 | 0.73 | 191.0K | 262,500 | — | ↗ |
| 2016-03-21 | CHAPLIN DAVID | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 262,500 | 0.73 | 191.0K | 262,500 | — | ↗ |
| 2015-07-20 | LOAR MATTHEW M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.37 | 205.5K | 150,000 | — | ↗ |
| 2015-06-04 | Ha Pamela | Officer | — | D | Employee Stock Option (Right to Buy) | 5,000 | 4.18 | 20.9K | 0 | — | ↗ |
| 2015-05-28 | Schwieterman William D | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 1.43 | 429.0K | 300,000 | — | ↗ |
| 2015-05-28 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 77,996 | 1.43 | 111.5K | 77,996 | — | ↗ |
| 2015-05-28 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 77,996 | 1.43 | 111.5K | 77,996 | — | ↗ |
| 2015-05-28 | CHAPLIN DAVID | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 225,000 | 1.43 | 321.8K | 225,000 | — | ↗ |
| 2014-07-02 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 5,280 | 2.60 | 13.7K | 5,280 | — | ↗ |
| 2014-07-02 | McMahon Gerald PhD | Director | A-Award | A | Common Stock, $0.01 par value per share | 3,847 | 0.00 | — | 18,611 | — | ↗ |
| 2014-07-02 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 5,280 | 2.60 | 13.7K | 5,280 | — | ↗ |
| 2014-07-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 7,920 | 2.60 | 20.6K | 7,920 | — | ↗ |
| 2014-05-30 | RICHING BARBARA | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.66 | 199.5K | 75,000 | — | ↗ |
| 2014-05-15 | CHAPLIN DAVID | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 2.95 | 442.5K | 150,000 | — | ↗ |
| 2014-01-02 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 4,880 | 2.79 | 13.6K | 4,880 | — | ↗ |
| 2014-01-02 | McMahon Gerald PhD | Director | A-Award | A | Common Stock, $0.01 par value per share | 3,584 | 0.00 | — | 14,764 | — | ↗ |
| 2014-01-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.79 | 83.7K | 30,000 | — | ↗ |
| 2014-01-02 | CHAPLIN DAVID | Director | A-Award | A | Stock Option (Right to Buy) | 4,880 | 2.79 | 13.6K | 4,880 | — | ↗ |
| 2014-01-01 | DRISCOLL FREDERICK W | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-08-08 | LANGECKER PETER | Director / Officer | A-Award | A | Common Stock, $0.01 par value per share | 72,993 | 0.00 | — | 77,993 | — | ↗ |
| 2013-07-01 | Wood Alastair JJ | Director | A-Award | A | Stock Option (Right to Buy) | 890 | 2.70 | 2.4K | 890 | — | ↗ |
| 2013-07-01 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 10,060 | 2.70 | 27.2K | 10,060 | — | ↗ |
| 2013-07-01 | McMahon Gerald PhD | Director | A-Award | A | Common Stock, $0.01 par value per share | 7,407 | 0.00 | — | 11,180 | — | ↗ |
| 2013-07-01 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 5,030 | 2.70 | 13.6K | 5,030 | — | ↗ |
| 2013-07-01 | CHAPLIN DAVID | Director | A-Award | A | Stock Option (Right to Buy) | 10,060 | 2.70 | 27.2K | 10,060 | — | ↗ |
| 2013-06-28 | LANGECKER PETER | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 per share | 3,000 | 2.75 | 8.3K | 5,000 | — | ↗ |
| 2013-02-27 | RICHING BARBARA | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.18 | 62.7K | 15,000 | — | ↗ |
| 2013-02-27 | LANGECKER PETER | Officer | A-Award | A | Stock Option (Right to Buy) | 8,333 | 4.18 | 34.8K | 8,333 | — | ↗ |
| 2013-01-23 | CHAPLIN DAVID | Director | A-Award | A | Stock Option (Right to Buy) | 6,260 | 4.36 | 27.3K | 6,260 | — | ↗ |
| 2013-01-02 | Wood Alastair JJ | Director | A-Award | A | Stock Option (Right to Buy) | 5,140 | 0.00 | — | 5,140 | — | ↗ |
| 2013-01-02 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 5,140 | 5.30 | 27.2K | 5,140 | — | ↗ |
| 2013-01-02 | McMahon Gerald PhD | Director | A-Award | A | Common Stock, $0.01 par value per share | 3,773 | 0.00 | — | 3,773 | — | ↗ |
| 2012-07-30 | RICHING BARBARA | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-07-30 | LANGECKER PETER | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.55 | 55.0K | 100,000 | — | ↗ |
| 2012-07-02 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 50,500 | 0.55 | 27.8K | 50,500 | — | ↗ |
| 2012-07-02 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 25,200 | 0.55 | 13.9K | 25,200 | — | ↗ |
| 2012-07-01 | Wood Alastair JJ | Director | A-Award | A | Stock Option (Right to Buy) | 50,500 | 0.55 | 27.8K | 50,500 | — | ↗ |
| 2012-07-01 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 50,500 | 0.55 | 27.8K | 50,500 | — | ↗ |
| 2012-07-01 | McMahon Gerald PhD | Director | A-Award | A | Stock Option (Right to Buy) | 50,500 | 0.55 | 27.8K | 50,500 | — | ↗ |
| 2012-07-01 | HOWSON TAMAR D | Director | A-Award | A | Common Stock, $0.01 par value per share | 18,148 | 0.00 | — | 38,060 | — | ↗ |
| 2012-04-02 | Johnson David Louis | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-01-02 | Wood Alastair JJ | Director | A-Award | A | Stock Option (Right to Buy) | 28,300 | 0.99 | 28.0K | 28,300 | — | ↗ |
| 2012-01-02 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 28,300 | 0.99 | 28.0K | 28,300 | — | ↗ |
| 2012-01-02 | McMahon Gerald PhD | Director | A-Award | A | Stock Option (Right to Buy) | 28,300 | 0.99 | 28.0K | 28,300 | — | ↗ |
| 2012-01-02 | HOWSON TAMAR D | Director | A-Award | A | Common Stock, $0.01 par value per share | 10,101 | 0.00 | — | 19,912 | — | ↗ |
| 2011-12-08 | LANGECKER PETER | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.03 | 206.0K | 200,000 | — | ↗ |
| 2011-10-31 | Schwieterman William D | Director | A-Award | A | Stock Option (Right to Buy) | 17,300 | 1.65 | 28.5K | 17,300 | — | ↗ |
| 2011-10-31 | SHIEBLER WILLIAM N | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-10-31 | KESSEL MARK | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-10-31 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 8,600 | 1.65 | 14.2K | 8,600 | — | ↗ |
| 2011-09-20 | McMahon Gerald PhD | Director | A-Award | A | Stock Option (Right to Buy) | 17,000 | 1.14 | 19.4K | 17,000 | — | ↗ |
| 2011-09-02 | McMahon Gerald PhD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-01-02 | Wood Alastair JJ | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 115,000 | — | ↗ |
| 2011-01-02 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 179,208 | — | ↗ |
| 2011-01-02 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 236,002 | — | ↗ |
| 2011-01-02 | KESSEL MARK | Director / 10% Owner | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 115,000 | — | ↗ |
| 2011-01-02 | HOWSON TAMAR D | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 75,000 | — | ↗ |
| 2011-01-02 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.23 | 5.8K | 202,846 | — | ↗ |
| 2010-09-15 | MURPHY JAMES B | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.28 | 56.0K | 200,000 | — | ↗ |
| 2010-09-15 | LANGECKER PETER | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.28 | 56.0K | 200,000 | — | ↗ |
| 2010-09-15 | CHAPLIN DAVID | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.28 | 56.0K | 200,000 | — | ↗ |
| 2010-07-01 | Wood Alastair JJ | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.38 | 9.5K | 90,000 | — | ↗ |
| 2010-07-01 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.38 | 9.5K | 154,208 | — | ↗ |
| 2010-07-01 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.38 | 9.5K | 292,002 | — | ↗ |
| 2010-07-01 | KESSEL MARK | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 0.38 | 9.5K | 27,297,118 | — | ↗ |
| 2010-07-01 | HOWSON TAMAR D | Director | S-Sale | A | Common Stock, $0.01 par value per share | 25,000 | 0.39 | 9.8K | 50,000 | — | ↗ |
| 2010-04-27 | MURPHY JAMES B | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.06 | 424.0K | 400,000 | — | ↗ |
| 2010-04-27 | LANGECKER PETER | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.06 | 424.0K | 400,000 | — | ↗ |
| 2010-04-27 | CHAPLIN DAVID | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.06 | 424.0K | 400,000 | — | ↗ |
| 2010-04-02 | HOWSON TAMAR D | Director | A-Award | A | Common Stock, $0.01 par value per share | 25,000 | 1.17 | 29.3K | 25,000 | — | ↗ |
| 2010-01-02 | Wood Alastair JJ | Director | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 65,000 | — | ↗ |
| 2010-01-02 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 129,208 | — | ↗ |
| 2010-01-02 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 186,002 | — | ↗ |
| 2010-01-02 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 409,232 | — | ↗ |
| 2010-01-02 | KESSEL MARK | Director / 10% Owner | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 65,000 | — | ↗ |
| 2010-01-02 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 35,000 | 1.14 | 39.9K | 152,846 | — | ↗ |
| 2009-12-31 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 7,017 | 1.14 | 8.0K | 94,208 | — | ↗ |
| 2009-12-31 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 8,662 | 1.14 | 9.9K | 374,232 | — | ↗ |
| 2009-12-31 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 7,017 | 1.14 | 8.0K | 117,846 | — | ↗ |
| 2009-12-08 | Wood Alastair JJ | Director | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 30,000 | — | ↗ |
| 2009-12-08 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 87,191 | — | ↗ |
| 2009-12-08 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 151,002 | — | ↗ |
| 2009-12-08 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 365,570 | — | ↗ |
| 2009-12-08 | KESSEL MARK | Director / 10% Owner | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 30,000 | — | ↗ |
| 2009-12-08 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 30,000 | 1.14 | 34.2K | 110,829 | — | ↗ |
| 2009-09-30 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 3,169 | 1.42 | 4.5K | 57,191 | — | ↗ |
| 2009-09-30 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 5,369 | 1.42 | 7.6K | 335,570 | — | ↗ |
| 2009-09-30 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 4,049 | 1.42 | 5.7K | 80,829 | — | ↗ |
| 2009-07-20 | Symphony Capital Partners LP | Director / 10% Owner | J-Other | A | Common Stock, par value .01 per share | 10,000,000 | 0.00 | — | 27,117,118 | — | ↗ |
| 2009-07-20 | KESSEL MARK | Director / 10% Owner | J-Other | A | Common Stock, par value $0.01 per share | 10,000,000 | 1.25 | 12.48M | 27,117,118 | — | ↗ |
| 2009-06-30 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,720 | 2.18 | 3.7K | 54,022 | — | ↗ |
| 2009-06-30 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,432 | 2.18 | 3.1K | 121,002 | — | ↗ |
| 2009-06-30 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 2,580 | 2.18 | 5.6K | 330,201 | — | ↗ |
| 2009-06-30 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,720 | 2.18 | 3.7K | 76,780 | — | ↗ |
| 2009-06-29 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 323 | 2.32 | 749.36 | 52,302 | — | ↗ |
| 2009-06-29 | LANGECKER PETER | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-06-29 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 323 | 2.32 | 749.36 | 327,621 | — | ↗ |
| 2009-06-29 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 323 | 2.32 | 749.36 | 75,060 | — | ↗ |
| 2009-05-28 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 336 | 2.23 | 749.28 | 51,979 | — | ↗ |
| 2009-05-28 | SHIEBLER WILLIAM N | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.23 | 223.0K | 100,000 | — | ↗ |
| 2009-05-28 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 336 | 2.23 | 749.28 | 74,737 | — | ↗ |
| 2009-05-04 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 555 | 0.90 | 499.50 | 119,570 | — | ↗ |
| 2009-05-04 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 555 | 0.90 | 499.50 | 327,298 | — | ↗ |
| 2009-05-04 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 555 | 0.90 | 499.50 | 74,401 | — | ↗ |
| 2009-05-01 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 806 | 0.93 | 749.58 | 51,643 | — | ↗ |
| 2009-05-01 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 806 | 0.93 | 749.58 | 119,015 | — | ↗ |
| 2009-05-01 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 806 | 0.93 | 749.58 | 326,743 | — | ↗ |
| 2009-05-01 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 806 | 0.93 | 749.58 | 73,846 | — | ↗ |
| 2009-04-28 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 914 | 0.82 | 749.48 | 50,837 | — | ↗ |
| 2009-04-28 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 914 | 0.82 | 749.48 | 118,209 | — | ↗ |
| 2009-04-28 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 914 | 0.82 | 749.48 | 325,937 | — | ↗ |
| 2009-04-28 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 914 | 0.82 | 749.48 | 73,040 | — | ↗ |
| 2009-04-16 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 961 | 0.78 | 749.58 | 49,923 | — | ↗ |
| 2009-04-16 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 961 | 0.78 | 749.58 | 117,295 | — | ↗ |
| 2009-04-16 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 961 | 0.78 | 749.58 | 325,023 | — | ↗ |
| 2009-04-16 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 961 | 0.78 | 749.58 | 72,126 | — | ↗ |
| 2009-03-31 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 5,514 | 0.68 | 3.7K | 48,962 | — | ↗ |
| 2009-03-31 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 6,892 | 0.68 | 4.7K | 116,334 | — | ↗ |
| 2009-03-31 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 8,271 | 0.68 | 5.6K | 324,062 | — | ↗ |
| 2009-03-31 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 5,514 | 0.68 | 3.7K | 71,165 | — | ↗ |
| 2009-03-16 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,086 | 0.69 | 749.34 | 43,448 | — | ↗ |
| 2009-03-16 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,086 | 0.69 | 749.34 | 109,442 | — | ↗ |
| 2009-03-16 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,086 | 0.69 | 749.34 | 315,791 | — | ↗ |
| 2009-03-16 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,086 | 0.69 | 749.34 | 65,651 | — | ↗ |
| 2009-03-10 | SHIEBLER WILLIAM N | Director | A-Award | A | Common Stock, $0.01 par value per share | 793 | 0.63 | 499.59 | 108,356 | — | ↗ |
| 2009-03-10 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 793 | 0.63 | 499.59 | 314,705 | — | ↗ |
| 2009-03-10 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 793 | 0.63 | 499.59 | 64,565 | — | ↗ |
| 2009-03-02 | Schwieterman William D | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,209 | 0.62 | 749.58 | 42,362 | — | ↗ |
| 2009-03-02 | LAFFER ARTHUR B | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,209 | 0.62 | 749.58 | 313,912 | — | ↗ |
| 2009-03-02 | FICKLING ROY H | Director | A-Award | A | Common Stock, $0.01 par value per share | 1,209 | 0.62 | 749.58 | 63,772 | — | ↗ |
Executive team
Top executives
Shares Outstanding
444.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | William D. Schwieterman, M.D. Former President and Chief Executive Officer | 74.2K | — | — | — | — | — | 484.2K | 0.00% | ↗ |
| 2 | 2019 | Matthew M. Loar Former Chief Financial Officer | 87.7K | — | — | — | — | — | 279.4K | 0.00% | ↗ |
| 3 | 2019 | Fatih Uckun, Ph. D. M.D. Former Chief Medical Officer (4/23/2019) | 135.4K | — | — | — | — | — | 217.8K | 0.00% | ↗ |
| 4 | 2019 | Vuong Trieu, Ph. D. President and Chief Executive Officer | 114.7K | — | — | — | — | — | 206.5K | 0.00% | ↗ |
| 5 | 2019 | Amit Shah Chief Financial Officer | 35.1K | — | — | — | — | — | 192.9K | 0.00% | ↗ |
| 6 | 2019 | Chulho Park, Ph. D. Chief Technology Officer | 89.4K | — | — | — | — | — | 161.6K | 0.00% | ↗ |
| 7 | 2018 | William D. Schwieterman, M.D. Former President and Chief Executive Officer | 205.0K | — | — | — | — | — | 464.1K | 0.00% | ↗ |
| 8 | 2018 | Matthew M. Loar Former Chief Financial Officer | 162.5K | — | — | — | — | — | 279.4K | 0.00% | ↗ |
| 9 | 2017 | William D. Schwieterman, M.D. President and Chief Executive Officer | 362.7K | — | — | 154.5K | — | 130.8K | 648.0K | 23.84% | ↗ |
| 10 | 2017 | Matthew M. Loar Chief Financial Officer | 287.5K | — | — | 98.3K | — | — | 385.8K | 25.48% | ↗ |
| 11 | 2017 | David J. Chaplin, Ph.D. Chief Scientific Officer | 192.9K | — | — | 73.7K | — | — | 266.6K | 27.66% | ↗ |
| 12 | 2016 | William D. Schwieterman, M.D. President and Chief Executive Officer | 410.0K | 102.5K | — | 227.5K | — | 126.3K | 866.3K | 26.26% | ↗ |
| 13 | 2016 | Matthew M. Loar Chief Financial Officer | 325.0K | 56.9K | — | 142.6K | — | — | 524.5K | 27.20% | ↗ |
| 14 | 2016 | David J. Chaplin, Ph.D. Chief Scientific Officer | 220.0K | 38.5K | — | 142.6K | — | — | 401.1K | 35.56% | ↗ |
| 15 | 2015 | William D. Schwieterman, M.D. President and Chief Executive Officer | 264.9K | 140.0K | — | 331.8K | — | 135.6K | 872.3K | 38.03% | ↗ |
| 16 | 2015 | William D. Schwieterman, M.D. President and Chief Executive Officer | 264.9K | 140.0K | — | 331.8K | — | 135.6K | 872.3K | 38.03% | ↗ |
| 17 | 2015 | David Chaplin Chief Scientific Officer | 289.7K | 98.8K | — | 238.5K | — | 36.5K | 663.4K | 35.95% | ↗ |
| 18 | 2015 | David J. Chaplin, Ph.D. Chief Scientific Officer | 289.7K | 98.8K | — | 238.5K | — | 36.5K | 663.4K | 35.95% | ↗ |
| 19 | 2015 | Barbara Riching Former Chief Financial Officer | 129.4K | — | — | 159.0K | — | 154.5K | 442.9K | 35.90% | ↗ |
| 20 | 2015 | Matthew M. Loar Chief Financial Officer | 148.8K | 68.2K | — | 158.0K | — | — | 374.9K | 42.13% | ↗ |
| 21 | 2015 | Matthew M. Loar Chief Financial Officer | 148.8K | 68.2K | — | 158.0K | — | — | 374.9K | 42.13% | ↗ |
| 22 | 2014 | David Chaplin Chief Scientific Officer | 257.6K | 189.6K | — | 310.5K | — | 45.8K | 802.5K | 38.69% | ↗ |
| 23 | 2014 | David Chaplin Chief Scientific Officer | 257.6K | 189.6K | — | 27.4K | — | 46.4K | 521.0K | 5.26% | ↗ |
| 24 | 2014 | Barbara Riching Former Chief Financial Officer | 232.0K | 77.7K | — | 139.7K | — | — | 449.4K | 31.09% | ↗ |
| 25 | 2014 | Peter Langecker Former CEO | 183.2K | — | — | — | — | 238.3K | 421.5K | 0.00% | ↗ |
| 26 | 2014 | Barbara Riching CFO | 232.0K | 77.7K | — | 64.6K | — | 929.00 | 375.2K | 17.21% | ↗ |
| 27 | 2013 | Peter Langecker Chief Executive Officer | 367.7K | 170.5K | 199.9K | 176.1K | — | 1.4K | 915.6K | 41.07% | ↗ |
| 28 | 2013 | Peter Langecker Former CEO | 367.7K | 170.5K | 199.9K | 176.1K | — | 1.4K | 915.6K | 41.07% | ↗ |
| 29 | 2013 | Barbara Riching Chief Financial Officer | 241.3K | — | — | 6.5K | — | — | 247.9K | 2.63% | ↗ |
| 30 | 2013 | Barbara Riching CFO | 241.3K | — | — | 6.5K | — | — | 247.9K | 2.63% | ↗ |
| 31 | 2012 | Peter Langecker Chief Executive Officer | 350.0K | — | — | 200.6K | — | 1.5K | 552.1K | 36.34% | ↗ |
| 32 | 2012 | Barbara Riching Chief Financial Officer | 218.3K | — | — | — | — | — | 218.3K | 0.00% | ↗ |
| 33 | 2005 | Frederick W. Driscoll President and Chief Executive Officer | 325.0K | 80.0K | 416.0K | — | — | 1.0K | 822.0K | 50.61% | ↗ |
| 34 | 2005 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 325.0K | 80.0K | 416.0K | — | — | 800.00 | 821.8K | 50.62% | ↗ |
| 35 | 2005 | Scott Young Chief Operating Officer | 220.8K | 50.0K | 208.0K | — | — | 228.00 | 479.0K | 43.42% | ↗ |
| 36 | 2005 | James B. Murphy Vice President and Chief Financial Officer | 200.8K | 34.0K | 208.0K | — | — | 306.00 | 443.1K | 46.94% | ↗ |
| 37 | 2004 | Frederick W. Driscoll President and Chief Executive Officer | 325.0K | 40.0K | — | — | — | 938.00 | 365.9K | 0.00% | ↗ |
| 38 | 2004 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 325.0K | 40.0K | — | — | — | 727.00 | 365.7K | 0.00% | ↗ |
| 39 | 2004 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research | 325.0K | 40.0K | — | — | — | — | 365.0K | 0.00% | ↗ |
| 40 | 2004 | Scott Young Chief Operating Officer | 202.3K | 20.0K | — | — | — | 207.00 | 222.5K | 0.00% | ↗ |
| 41 | 2004 | James B. Murphy Vice President and Chief Financial Officer | 151.6K | 20.0K | — | — | — | 278.00 | 171.9K | 0.00% | ↗ |
| 42 | 2003 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 311.3K | 100.0K | — | — | — | 661.00 | 412.0K | 0.00% | ↗ |
| 43 | 2003 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research | 311.3K | 100.0K | — | — | — | — | 411.3K | 0.00% | ↗ |
| 44 | 2003 | Frederick W. Driscoll President and Chief Executive Officer | 291.3K | 100.0K | — | — | — | 853.00 | 392.2K | 0.00% | ↗ |
| 45 | 2003 | Scott Young Chief Operating Officer | 170.6K | 35.0K | — | — | — | 188.00 | 205.8K | 0.00% | ↗ |
| 46 | 2003 | Scott Young Chief Operating Officer | 170.6K | 35.0K | — | 50.0K | — | — | 205.6K | 24.32% | ↗ |
| 47 | 2003 | James B. Murphy Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 48 | 2002 | Björn Nordenvall, Ph.D. Former President and Chief Executive Officer | 335.6K | 928.2K | — | 30.0K | — | — | 1.26M | 2.37% | ↗ |
| 49 | 2002 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research | 280.0K | 25.0K | 47.3K | — | — | 9.8K | 362.0K | 13.05% | ↗ |
| 50 | 2002 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 280.0K | 25.0K | 47.3K | 100.0K | — | 9.8K | 362.0K | 40.68% | ↗ |
| 51 | 2002 | Frederick W. Driscoll President and Chief Executive Officer | 250.0K | 25.0K | 21.0K | 100.0K | — | — | 296.0K | 40.88% | ↗ |
| 52 | 2002 | Frederick W. Driscoll President and Chief Executive Officer | 250.0K | — | 42.0K | — | — | — | 292.0K | 14.38% | ↗ |
| 53 | 2002 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 280.0K | — | — | 100.0K | — | — | 280.0K | 35.71% | ↗ |
| 54 | 2002 | Scott Young Chief Operating Officer | 150.0K | — | 21.0K | — | — | — | 171.0K | 12.28% | ↗ |
| 55 | 2002 | Scott Young Vice President of Clinical Regulatory | 150.0K | — | — | 12.0K | — | — | 150.0K | 8.00% | ↗ |
| 56 | 2002 | James B. Murphy Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 57 | 2001 | Björn Nordenvall, Ph.D. Former President and Chief Executive Officer | 318.6K | — | 42.0K | 55.0K | — | — | 360.6K | 26.90% | ↗ |
| 58 | 2001 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 271.9K | 25.0K | — | 45.0K | — | — | 296.9K | 15.16% | ↗ |
| 59 | 2001 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 271.9K | — | — | 45.0K | — | — | 271.9K | 16.55% | ↗ |
| 60 | 2001 | Frederick W. Driscoll President and Chief Executive Officer | 250.0K | — | — | 40.0K | — | — | 250.0K | 16.00% | ↗ |
| 61 | 2001 | Frederick W. Driscoll President and Chief Executive Officer | 250.0K | — | — | 40.0K | — | — | 250.0K | 16.00% | ↗ |
| 62 | 2001 | Scott Young Vice President of Clinical Regulatory | 123.0K | — | — | — | — | — | 123.0K | 0.00% | ↗ |
| 63 | 2000 | Björn Nordenvall, Ph.D. Former President and Chief Executive Officer | 300.0K | 25.0K | 47.3K | 40.0K | — | 9.8K | 382.0K | 22.84% | ↗ |
| 64 | 2000 | David Chaplin, Ph.D. Chief Scientific Officer and Head of Research and Development | 150.0K | — | — | 45.0K | — | — | 150.0K | 30.00% | ↗ |
| 65 | 2000 | Scott Young Vice President of Clinical Regulatory | 110.0K | — | — | — | — | — | 110.0K | 0.00% | ↗ |
| 66 | 2000 | Frederick W. Driscoll President and Chief Executive Officer | 41.8K | — | — | 40.0K | — | — | 41.8K | 95.63% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amit Shah | Chief Financial Officer | — | male |
| Anthony E. Maida | Chief Medical Officer Translation Medicine & Director | — | — |
| Burcak Beser | Chief Technology Officer of AI Division | — | male |
| Larn Hwang | Chief Scientific Officer | — | — |
| Saranjit Saund | CBO & GM of AI Division | — | male |
| Seymour Howard Fein | Chief Regulatory Officer & Chief Medical Officer (Consultant) | — | — |
| Steven W. King | Consultant & Director | — | male |
| Vuong Trieu | CEO, President & Chairman | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OTLC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
